Imugene Valuation
| IMU Stock | 0.38 0.01 2.70% |
Imugene seems to be fairly valued based on Macroaxis valuation methodology. Our model calculates the value of Imugene from evaluating the firm fundamentals such as Return On Equity of -1.0, shares outstanding of 224.96 M, and Return On Asset of -0.43 as well as inspecting its technical indicators and probability of bankruptcy.
Price Book 1.511 | Enterprise Value 75 M | Enterprise Value Ebitda (15.51) | Price Sales 56.4026 |
Fairly Valued
Today
Please note that Imugene's price fluctuation is out of control at this time. Calculation of the real value of Imugene is based on 3 months time horizon. Increasing Imugene's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Imugene's intrinsic value may or may not be the same as its current market price of 0.38, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 0.38 | Real 0.36 | Hype 0.35 | Naive 0.38 |
The intrinsic value of Imugene's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Imugene's stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Imugene helps investors to forecast how Imugene stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Imugene more accurately as focusing exclusively on Imugene's fundamentals will not take into account other important factors: Imugene Cash |
|
Imugene Total Value Analysis
Imugene is currently anticipated to have takeover price of 75.01 M with market capitalization of 84.36 M, debt of 1.55 M, and cash on hands of 49.57 M. Please note that takeover price may be misleading and is a subject to mistakes in financial statements. We encourage investors to thoroughly investigate all of the Imugene fundamentals before making investing decisions based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
75.01 M | 84.36 M | 1.55 M | 49.57 M |
Imugene Investor Information
About 14.0% of the company shares are held by company insiders. The company has price-to-book (P/B) ratio of 1.51. Some equities with similar Price to Book (P/B) outperform the market in the long run. Imugene recorded a loss per share of 0.6. The entity had not issued any dividends in recent years. The firm had 1:34 split on the 2nd of July 2025. Based on the measurements of operating efficiency obtained from Imugene's historical financial statements, Imugene is not in a good financial situation at this time. It has a very high odds of going through financial crisis in August.Imugene Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Imugene has an asset utilization ratio of 7.14 percent. This implies that the Company is making USD0.0714 for each dollar of assets. An increasing asset utilization means that Imugene is more efficient with each dollar of assets it utilizes for everyday operations.Imugene Ownership Allocation
Imugene has a total of 224.96 Million outstanding shares. Imugene retains 14.47 (percent) of its outstanding shares held by insiders and 4.87 (percent) owned by outside corporations. Please note that no matter how many assets the company holds, if the real value of the firm is less than the current market value, you may not be able to make money on it.Imugene Profitability Analysis
The company reported the revenue of 10.81 M. Net Loss for the year was (149.68 M) with loss before overhead, payroll, taxes, and interest of (1.84 M).About Imugene Valuation
The stock valuation mechanism determines Imugene's current worth on a daily basis. In general, an absolute valuation approach attempts to find the value of Imugene based exclusively on its fundamental and basic technical indicators. As compared to an absolute model, our relative valuation model uses a comparative analysis of Imugene. We calculate exposure to Imugene's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Imugene's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | 5.7 M | 6 M |
Additional Tools for Imugene Stock Analysis
When running Imugene's price analysis, check to measure Imugene's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Imugene is operating at the current time. Most of Imugene's value examination focuses on studying past and present price action to predict the probability of Imugene's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Imugene's price. Additionally, you may evaluate how the addition of Imugene to your portfolios can decrease your overall portfolio volatility.